Natco Pharma Ltd.

₹935.95

10.9 (1.2%)

NATCOPHARM Share Price

Pharmaceuticals & Biotechnology

As on July 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 16,799 Cr

P/E Ratio8.89

Dividend Yield0.32 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	925.62	Bullish
10-DMA	938.61	Bearish
20-DMA	950.11	Bearish
50-DMA	955.75	Bearish
100-DMA	1,007.65	Bearish
200-DMA	936.47	Bearish

Historical Performance

1 Year

-2.4%

3 Years

13.1%

5 Years

-8.1%

10 Years

48.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	44,295	39,988	27,071	19,448	20,521
Total Expenditure	22,357	22,474	17,954	16,813	14,483
Other Income	3,567	1,281	1,285	990	1,060
Operating Profit	25,505	18,795	10,402	3,625	7,098
Interest	239	192	145	177	133
Depreciation	2,352	1,868	1,638	1,426	1,169
Profit Before Tax	22,914	16,735	8,619	2,022	5,796
Consolidated Net Profit	18,854	13,883	7,153	1,700	4,409
Adjusted EPS	105	78	39	9	24

Compounded Sales Growth

10 Years:43.4

5 Years:18.3

3 Years:17.9

TTM:2.1

Compounded Profit Growth

10 Years:69.5

5 Years:32.5

3 Years:61.8

TTM:6.3

Stock Price CAGR

10 Years:4

5 Years:-1.8

3 Years:4.2

TTM:-3.8

Return on Equity

10 Years:9

5 Years:24.2

3 Years:39.2

last year:105.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	358	358	365	365	365
Total Reserves	75,712	58,173	48,373	42,237	40,676
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	249	610	1,005	1,351	1,429
Other Current Liabilities	2,386	2,389	2,273	1,267	995
Short Term Borrowings	2,731	3,632	1,650	4,040	2,658
Total Liabilities	85,807	68,869	56,574	51,091	47,919
Capital Work in Progress	2,254	1,373	643	1,295	2,234
Long Term Loans & Advances	738	1,127	783	720	443
Currents Investments	3,208	4,435	3,050	2,037	1,518
Short Term Loans and Advances	6,257	6,382	4,856	6,062	6,037
Total Current Assets	52,700	40,235	30,003	24,867	23,448
Total Assets	85,807	68,869	56,574	51,091	47,919
Adjusted Book Value	425	327	267	233	225

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of 8.89, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of 3.9%, indicating poor shareholder returns.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹25505 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹44295 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 961773.6

No. of Shares: 1028 (Approx)

Performance:-3.8%

-38226.4

NIFTY Performance: -2.4%

1 day Top Gainers